ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sodium phosphate

Also written as “Sodium Phosphates Injection”, “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)” and “Oral sodium phosphate solution”.

Its studies are led by 4 companies.

Drug pageSodium phosphate: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 23, 20135 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Laboratoires Mayoly Spindlerits history only20 open or runningphase 3since Apr 23, 2013Jul 13, 2011none ahead
Bausch Health Companiesits history only10 open or runningphase 4since Aug 30, 2011Aug 30, 2011none ahead
Baxter Healthcareits history only10 open or runningphase 1since Feb 11, 2025Feb 11, 2025none ahead
Universal Integrated10 open or runningphase 3since Jun 6, 2019Jun 6, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Universal Integrated only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 6, 2019First study: phase 3 study in Bowel PreparationFirst studyNCT03992365 · 472 enrolled · Taiwan

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Universal Integrated leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03992365Bowel Preparation · Taiwan3CompletedOct 15, 2019472

How it is read

Names in the registry

  • “Sodium Phosphates Injection”, 1 entry
  • “Quiklean® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)”, 1 entry
  • “Oral sodium phosphate solution”, 1 entry
  • “oral sodium phosphate tablets”, 1 entry
  • “Sodium phosphate”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.